Trial Outcomes & Findings for Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers (NCT NCT04553471)

NCT ID: NCT04553471

Last Updated: 2024-08-29

Results Overview

Recruitment status

COMPLETED

Study phase

Target enrollment

70 participants

Primary outcome timeframe

At 6 months

Results posted on

2024-08-29

Participant Flow

Participant milestones

Participant milestones
Measure	SBRT 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Overall Study STARTED	70
Overall Study COMPLETED	66
Overall Study NOT COMPLETED	4

Reasons for withdrawal

Reasons for withdrawal
Measure	SBRT 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Overall Study Did not start treatment on protocol	3
Overall Study Death	1

Baseline Characteristics

Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	SBRT n=70 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Age, Continuous	65.5 years n=5 Participants
Sex: Female, Male Female	27 Participants n=5 Participants
Sex: Female, Male Male	43 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	69 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	1 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	11 Participants n=5 Participants
Race (NIH/OMB) White	57 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants
Region of Enrollment United States	70 participants n=5 Participants

PRIMARY outcome

Timeframe: At 6 months

Population: Participants must have received treatment and had a 6 month disease assessment to be evaluable for this outcome measure.

Outcome measures

Outcome measures
Measure	SBRT n=32 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Rate of Local Control	29 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Through 6 months

-Graded using CTCAE v5.0

Outcome measures

Outcome measures
Measure	SBRT n=66 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Number of Participants With Treatment-related, Non-hematologic Grade ≥ 3 Toxicity	2 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

Population: If a participant did not complete the questionnaire at the timepoint then they are not included.

* Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Physical Function is a 10-item questionnaire assessing current self-reported physical function with answers ranging from 1 = cannot do to 5 = not at all/without any difficulty. * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Physical Function Assessment correlates to a higher physical function, or positive outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or better functioning, than the reference population mean.

Outcome measures

Outcome measures
Measure	SBRT n=38 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=39 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=31 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=21 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=15 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Mean Change From Baseline - PROMIS Physical Function Assessment	2.22 T-Score Standard Deviation 5.976098077	-0.27 T-Score Standard Deviation 6.464353622	2.01 T-Score Standard Deviation 8.493109161	2.76 T-Score Standard Deviation 8.144051291	-0.72 T-Score Standard Deviation 6.097212478	—

SECONDARY outcome

Timeframe: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

Population: If a participant did not complete the questionnaire at the timepoint then they are not included.

* Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Global Health is a 2-item questionnaire assessing current self-reported physical function with answers ranging from 1=poor/not all all to 5=excellent/completely * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Global Health Physical Assessment correlates to a higher global health physical assessment, or positive outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or better physical assessment, than the reference population mean

Outcome measures

Outcome measures
Measure	SBRT n=41 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=39 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=31 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=20 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=16 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Mean Change From Baseline-PROMIS Global Health Physical Assessment	1.36 T-Score Standard Deviation 4.885644726	0.40 T-Score Standard Deviation 5.629643682	0.95 T-Score Standard Deviation 6.704716684	2.63 T-Score Standard Deviation 7.152040563	1.06 T-Score Standard Deviation 5.996095952	—

SECONDARY outcome

Timeframe: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

Population: If a participant did not complete the questionnaire at the timepoint then they are not included.

* Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Depression is a 4-item questionnaire assessing current self-reported depression with answers ranging from 1=never to 5=always * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Depression Assessment correlates to more depression, or negative outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or worse depression, than the reference population mean

Outcome measures

Outcome measures
Measure	SBRT n=40 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=39 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=32 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=20 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=16 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Mean Change From Baseline-PROMIS Depression Assessment	1.01 T-Score Standard Deviation 6.575515969	0.72 T-Score Standard Deviation 7.013388007	-0.15 T-Score Standard Deviation 7.290691563	1.01 T-Score Standard Deviation 9.929482946	-2.43 T-Score Standard Deviation 8.78069853	—

SECONDARY outcome

Timeframe: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

Population: If a participant did not complete the questionnaire at the timepoint then they are not included.

* Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Anxiety is a 29-item questionnaire assessing current self-reported anxiety with answers ranging from 1=never to 5=always * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Anxiety Assessment correlates to more anxiety, or negative outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or worse anxiety, than the reference population mean.

Outcome measures

Outcome measures
Measure	SBRT n=42 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=40 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=32 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=20 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=16 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Mean Change From Baseline-PROMIS Anxiety Assessment	1.16 T-Score Standard Deviation 7.520188855	0.12 T-Score Standard Deviation 6.799064792	-1.66 T-Score Standard Deviation 8.797717813	-0.15 T-Score Standard Deviation 8.436791296	-4.34 T-Score Standard Deviation 9.955565864	—

SECONDARY outcome

Timeframe: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

Population: If a participant did not complete the questionnaire at the timepoint then they are not included.

* Each value is the mean of the changes from baseline Numeric Pain Scale score to timepoint Numeric Pain Scale score. * The Numeric Pain Scale is an 11-point scale for patient self-reporting of pain * The Numeric Pain Rating Scale (NPRS) measures pain intensity in adults using a scale from 0 or "no pain" to 10 or "worst possible pain." This measure is unidimensional and evaluated on the 0-10 scale. A higher value on the scale correlates with a worse pain and a worse outcome.

Outcome measures

Outcome measures
Measure	SBRT n=23 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=24 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=18 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=14 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=13 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Mean Change From Baseline-Numeric Pain Scale	0.87 score on a scale Standard Deviation 3.911571967	-0.38 score on a scale Standard Deviation 4.209848701	-0.83 score on a scale Standard Deviation 2.357715744	-0.29 score on a scale Standard Deviation 3.709210396	-0.77 score on a scale Standard Deviation 2.832956234	—

SECONDARY outcome

Timeframe: Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

Population: If a participant did not complete the questionnaire at the timepoint then they are not included. If the participant did not answer a question on the questionnaire then they are not included for that question.

Outcome measures

Outcome measures
Measure	SBRT n=20 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=15 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=15 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=12 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=9 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months n=5 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of decreased appetite	2 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of vomiting	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of heartburn	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of heartburn	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of bloating	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	1.5 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of bloating	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of hiccups	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of hiccups	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of diarrhea	1 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of abdominal pain	2 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Abdominal pain interference	1 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Bowel movement control loss interference	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of numbness/tingling in hands or feet	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of dizziness	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Dizziness interference	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of concentration problems	1 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Concentration problems interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of pain	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Pain interference	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of insomnia	2 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	1.5 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Insomnia interference	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of fatigue	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 2.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 2.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Fatigue interference	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2.5 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of anxiety	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of anxiety	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Anxiety interference	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of depression	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of depression	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Depression interference	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of sadness or unhappiness	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	1.5 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of sadness or unhappiness	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Sadness or happiness interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Decreased appetite interference	1 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of nausea	1 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of nausea	1 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Numbness or tingling in hands or feet interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of vomiting	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of constipation	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of abdominal pain	2 score on a scale Interval 1.0 to 5.0	2.5 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of bowel movement control loss	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Severity of memory problems	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Memory problem interference	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) Frequency of pain	3 score on a scale Interval 1.0 to 5.0	4 score on a scale Interval 1.0 to 5.0	4 score on a scale Interval 2.0 to 5.0	3 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0

SECONDARY outcome

Timeframe: Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

* The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * How often options include 1=never, 2=rarely, 3=occasionally, 4=frequently, 5=almost constantly * Severity of difficulty getting/keeping erection, ejaculation problems, decreased sexual interest, vaginal pain 1=none, 2=mild, 3=moderate, 4=severe, 5=very severe * Experienced unusual vaginal discharge options include 1=not at all, 2=a little bit, 3 = somewhat, 4=quite a bit, 5=very much

Outcome measures

Outcome measures
Measure	SBRT n=21 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=14 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=13 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=10 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=7 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months n=6 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of numbness/tingling in hands or feet	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Numbness or tingling in hands or feet interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of dizziness	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 2.0	2.5 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Dizziness interference	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of memory problems	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1.5 score on a scale Interval 1.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequency of pain	4 score on a scale Interval 1.0 to 5.0	3.5 score on a scale Interval 2.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	3.5 score on a scale Interval 3.0 to 5.0	3 score on a scale Interval 2.0 to 5.0	4 score on a scale Interval 3.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of insomnia	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Insomnia interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2.5 score on a scale Interval 1.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Depression interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 1.0	1.5 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of pain during vaginal sex	1 score on a scale Interval 1.0 to 1.0	—	1 score on a scale Only 1 participant was evaluable.	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 1.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequency of urination frequency	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	2.5 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequent urination interfering	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequency of urine leakage	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Urine leakage frequency	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of concentration problems	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 5.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1.5 score on a scale Interval 1.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Concentration problems interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1.5 score on a scale Interval 1.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Memory problem interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1.5 score on a scale Interval 1.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of pain	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 2.0 to 5.0	3 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 2.0 to 4.0	3 score on a scale Interval 2.0 to 5.0	3 score on a scale Interval 2.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Pain interference	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2.5 score on a scale Interval 2.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of difficulty getting/keeping an erection	1 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	2.5 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of fatigue	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 2.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	3.5 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 2.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Fatigue interference	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	3.5 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 4.0	2.5 score on a scale Interval 2.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequency of anxiety	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	3 score on a scale Interval 2.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of anxiety	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	2.5 score on a scale Interval 2.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Anxiety interference	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequency of depression	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of depression	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequency of sadness or unhappiness	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of sadness or unhappiness	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Sadness or happiness interference	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Experienced unusual vaginal discharge	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 1.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of vaginal dryness	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 1.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of pain/burning with urination	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequency of urge to urinate	1.5 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	2.5 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Urge to urinate interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1.5 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Frequency of ejaculation problems	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	2.5 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) Severity of decreased sexual interest	1.5 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0

SECONDARY outcome

Timeframe: Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

Outcome measures

Outcome measures
Measure	SBRT n=2 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=3 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=2 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=2 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=1 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Fatigue interference	3.5 score on a scale Interval 2.0 to 5.0	3.5 score on a scale Interval 2.0 to 5.0	2 score on a scale Interval 2.0 to 2.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Dizziness interference	2.5 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 2.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Memory problem interference	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Frequency of pain	3 score on a scale Interval 2.0 to 4.0	4 score on a scale Interval 4.0 to 4.0	4.5 score on a scale Interval 4.0 to 5.0	4.5 score on a scale Interval 4.0 to 5.0	2 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of pain	2.5 score on a scale Interval 2.0 to 3.0	4 score on a scale Interval 4.0 to 5.0	4.5 score on a scale Interval 4.0 to 5.0	4 score on a scale Interval 4.0 to 4.0	2 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Pain interference	2.5 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 3.0 to 3.0	4 score on a scale Interval 3.0 to 5.0	3 score on a scale Interval 3.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of insomnia	2 score on a scale Interval 1.0 to 3.0	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 3.0 to 3.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Insomnia interference	2 score on a scale Interval 1.0 to 3.0	2.5 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 2.0 to 4.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of fatigue	3.5 score on a scale Interval 2.0 to 5.0	3.5 score on a scale Interval 2.0 to 5.0	2 score on a scale Interval 2.0 to 2.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Frequency of depression	1.5 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0	1.5 score on a scale Interval 1.0 to 2.0	2 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of dry mouth	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 1.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of difficulty swallowing	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 2.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of mouth or throat sores	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Mouth or throat sores interference	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 1.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of skin cracking at corners of mouth	1 score on a scale Interval 1.0 to 1.0	3 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 1.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of hoarse voice	1.5 score on a scale Interval 1.0 to 2.0	3 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of numbness/tingling in hands or feet	3 score on a scale Interval 2.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	2.5 score on a scale Interval 1.0 to 4.0	3.5 score on a scale Interval 3.0 to 4.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Numbness or tingling in hands or feet interference	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of dizziness	3 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 2.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of concentration problems	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 2.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Concentration problems interference	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 2.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of memory problems	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 2.0	1.5 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Frequency of anxiety	2 score on a scale Interval 1.0 to 3.0	2.5 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of anxiety	2 score on a scale Interval 1.0 to 3.0	2.5 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Anxiety interference	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of depression	1.5 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Depression interference	1.5 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Frequency of sadness or unhappiness	3 score on a scale Interval 3.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 2.0 to 2.0	2.5 score on a scale Interval 2.0 to 3.0	2 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Severity of sadness or unhappiness	3.5 score on a scale Interval 3.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 2.0	2.5 score on a scale Interval 2.0 to 3.0	2 score on a scale Only 1 participant was evaluable.	—
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) Sadness or happiness interference	2.5 score on a scale Interval 2.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 1.0	2 score on a scale Interval 2.0 to 2.0	1 score on a scale Only 1 participant was evaluable.	—

SECONDARY outcome

Timeframe: Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months

Population: If a participant did not complete the questionnaire at the timepoint then they are not included.

Outcome measures

Outcome measures
Measure	SBRT n=18 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-30 Days n=11 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-3 Months n=11 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-6 Months n=10 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT-12 Months n=7 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.	SBRT - 12 Months n=5 Participants 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of hoarse voice	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of shortness of breath	3 score on a scale Interval 2.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Shortness of breath interference	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of wheezing	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Dizziness interference	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 1.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Concentration problems interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of memory problems	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Memory problem interference	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of pain	2 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	1.5 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 2.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of insomnia	3 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	3 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of fatigue	3 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 2.0 to 5.0	3 score on a scale Interval 2.0 to 5.0	2.5 score on a scale Interval 2.0 to 4.0	3 score on a scale Interval 2.0 to 3.0	3 score on a scale Interval 2.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Fatigue interference	2.5 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 2.0 to 5.0	2 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 2.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of anxiety	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of anxiety	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of depression	1.5 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of depression	1.5 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Depression interference	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Sadness or happiness interference	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of numbness/tingling in hands or feet	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Numbness or tingling in hands or feet interference	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of heartburn	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of decreased appetite	2 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Decreased appetite interference	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of nausea	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of dizziness	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of nausea	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of vomiting	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of vomiting	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of heartburn	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of bloating	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of bloating	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 2.0	2 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of hiccups	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of hiccups	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 1.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of concentration problems	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of pain	2 score on a scale Interval 1.0 to 5.0	3 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 2.0 to 5.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Pain interference	1 score on a scale Interval 1.0 to 5.0	3.5 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 5.0	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Insomnia interference	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 3.0	1.5 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Anxiety interference	1 score on a scale Interval 1.0 to 4.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Frequency of sadness or unhappiness	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 3.0
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) Severity of sadness or unhappiness	2 score on a scale Interval 1.0 to 3.0	2 score on a scale Interval 1.0 to 4.0	1.5 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 4.0	2 score on a scale Interval 1.0 to 3.0	1 score on a scale Interval 1.0 to 2.0

Adverse Events

SBRT

Serious events: 42 serious events

Other events: 31 other events

Deaths: 33 deaths

Serious adverse events

Serious adverse events
Measure	SBRT n=66 participants at risk 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Gastrointestinal disorders Abdominal pain	4.5% 3/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
General disorders Accidental morphine overdose	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Renal and urinary disorders Acute kidney injury	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Infections and infestations Adenovirus upper respiratory infection	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Anal pain	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Blood and lymphatic system disorders Anemia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Cardiac disorders Atrial fibrillation	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Investigations Blood bilirubin increased	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Infections and infestations COVID19	4.5% 3/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Cough	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
General disorders Disease progression	42.4% 28/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Diverticulitis	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Dysphagia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Dyspnea	6.1% 4/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Blood and lymphatic system disorders Febrile neutropenia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
General disorders Fever	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Musculoskeletal and connective tissue disorders Generalized muscle weakness	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Cardiac disorders Heart failure	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Hepatobiliary disorders Hepatic failure	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Hypercalcemia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Hyperkalemia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Hyponatremia	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Infections and infestations Infection attributed to port	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Nervous system disorders Intracranial hemorrhage	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Jejunal obstruction	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Blood and lymphatic system disorders Leukocytosis	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Infections and infestations Lung infection	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Cardiac disorders Mass on right ventricle	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Nausea	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Investigations Neutrophil count decreased	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Pancreatitis	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Pleural effusion	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Reproductive system and breast disorders Post-menopause bleeding	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Respiratory failure	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Infections and infestations Sepsis	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Injury, poisoning and procedural complications Spinal fracture	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Nervous system disorders Stroke	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
General disorders THA failure with pseudotumor formation	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Vascular disorders Thromboembolic event	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Tumor lysis syndrome	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Upper gastrointestinal hemorrhage	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Cardiac disorders Ventricular tachycardia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Vomiting	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Injury, poisoning and procedural complications Wound dehiscence	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.

Other adverse events

Other adverse events
Measure	SBRT n=66 participants at risk 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
Gastrointestinal disorders Abdominal pain	12.1% 8/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Acute pulmonary embolism	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Anorexia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Colitis	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Cough	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Diarrhea	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Dyspepsia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Dysphagia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Dyspnea	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Esophageal pain	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Injury, poisoning and procedural complications Fall	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
General disorders Fatigue	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Gastritis (epigastric pain)	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Musculoskeletal and connective tissue disorders Hip pain	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Hyperkalemia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Hyperuricemia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Hypokalemia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Metabolism and nutrition disorders Hyponatremia	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Investigations Hyponatremia	3.0% 2/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Blood and lymphatic system disorders Leukocytosis	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Investigations Lymphocyte count decreased	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Nausea	4.5% 3/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Musculoskeletal and connective tissue disorders Neck pain	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
General disorders Pain (pelvis/hip)	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Nervous system disorders Peripheral motor neuropathy	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Nervous system disorders Recurrent laryngeal nerve palsy	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Respiratory, thoracic and mediastinal disorders Respiratory failure	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Nervous system disorders Seizure	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Nervous system disorders Syncope	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Vascular disorders Thromboembolic event	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Renal and urinary disorders Urinary incontinence	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.
Gastrointestinal disorders Vomiting	1.5% 1/66 • Adverse events and all-cause mortality were collected from start of treatment through 360 days following completion of radiotherapy.

Additional Information

Pamela Samson, M.D.

Washington University School of Medicine

Phone: 314-747-1786

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place